Could an arthritis drug tame a tough transplant complication?
NCT ID NCT01954979
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests the drug abatacept in people with chronic graft-versus-host disease (cGVHD) that is not controlled by steroids. cGVHD is a condition where donor immune cells attack the recipient's body after a stem cell transplant. The trial has two phases: first, to find a safe dose of abatacept, and second, to see if it helps control the disease. Fifty-six participants will receive abatacept and be monitored for side effects and response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
abatacept
What this could lead to
If it works, this could offer a new treatment option for people with chronic graft-versus-host disease that does not respond to standard steroids.
What could go wrong
This is an early-phase trial with only 56 participants, so results may not apply to everyone. Abatacept can cause serious immune suppression and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT-VERSUS-HOST-DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States